ACST - アカスティ・ファ―マ （Acasti Pharma Inc.） アカスティ・ファ―マACSTのチャート
ACSTの企業情報
| symbol | ACST |
|---|---|
| 会社名 | Acasti Pharma Inc （アカスティ・ファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- アカスティ・ファ―マは、カナダのバイオ医薬品会社。脂質異常症と呼ばれる血中脂質異常や心血管障害の予防と治療法の研究、開発、商業化に従事する。主要製品は高トリグリセリド血症治療薬CaPreやOnemiaなど。それらの製品は、オキアミ油に由来するものである。主にカナダと米国で販売を行う。 Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with severe HTG. |
| 本社所在地 | 545 Promenade du Centropolis Suite 100 Laval Quebec H7T 0A3 CAN |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 37288 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.acastipharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/acst |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 1.24 |
| 時価総額（marketcap） | 45483038.8 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
ACSTのテクニカル分析
ACSTのニュース
Acasti Pharma announces CEO transition 2023/04/04 12:38:51 Seeking Alpha
Late-stage specialty pharma company advancing drug candidates for rare and orphan diseases, Acasti Pharma (ACST) appoints Prashant Kohli as CEO, succeeding Jan D''Alvise
Acasti Pharma Announces Resignation of Jean-Marie Canan from Board 2023/03/30 12:35:07 Investing.com
https://www.investing.com/news/assorted/acasti-pharma-announces-resignation-of-jeanmarie-canan-from-board-432SI-3045146
Acasti Pharma Inc. Announces the Resignation of a Director 2023/03/30 12:30:00 PR Newswire
LAVAL, QC, March 30, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST) a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that Mr. Jean-Marie (John) Canan had tendered…
Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference 2023/03/08 14:00:00 PR Newswire
LAVAL, QC, March 8, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D''alvise, CEO, will…
Acasti Pharma Recognizes Rare Disease Day 2023/02/28 18:00:00 PR Newswire
LAVAL, QC, Feb. 28, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, recognizes and celebrates Rare Disease Day…
Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript 2022/11/15 04:23:11 Seeking Alpha
Acasti Pharma Inc. (NASDAQ:NASDAQ:ACST) Q2 2023 Earnings Conference Call November 14, 2022 01:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Jan D''Alvise - President &…
Acasti Pharma Reports Q2 Loss of $0.11 By Investing.com 2022/11/14 12:31:11 Investing.com
Acasti Pharma Reports Q2 Loss of $0.11
Acasti Pharma GAAP EPS of -$0.11 (NASDAQ:ACST) 2022/11/14 12:15:29 Seeking Alpha
Acasti Pharma press release (ACST): Q3 GAAP EPS of -$0.11.The Company finished the second fiscal quarter ended September 30, 2022, with $34.9 million in cash, cash equivalents…
Acasti Pharma Reports Second Quarter 2023 Operational Results 2022/11/14 12:00:00 GlobeNewswire
Company to Host Conference Call Today at 1:00pm ET
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022 2022/11/07 21:15:00 GlobeNewswire
Call to be held on Monday, November 14th at 1:00 PM Eastern Time Call to be held on Monday, November 14th at 1:00 PM Eastern Time
Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript 2022/11/15 04:23:11 Seeking Alpha
Acasti Pharma Inc. (NASDAQ:NASDAQ:ACST) Q2 2023 Earnings Conference Call November 14, 2022 01:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Jan D''Alvise - President &…
Acasti Pharma Reports Q2 Loss of $0.11 By Investing.com 2022/11/14 12:31:11 Investing.com
Acasti Pharma Reports Q2 Loss of $0.11
Acasti Pharma GAAP EPS of -$0.11 (NASDAQ:ACST) 2022/11/14 12:15:29 Seeking Alpha
Acasti Pharma press release (ACST): Q3 GAAP EPS of -$0.11.The Company finished the second fiscal quarter ended September 30, 2022, with $34.9 million in cash, cash equivalents…